DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Varian to deliver six technical presentations at ICCR

Shandong Cancer Hospital proton center joins FlashForward Consortium for flash proton therapy research

Varian Medical Systems presents latest innovations in radiotherapy at DEGRO 25

Merit Medical awarded interventional fluid management agreement with Premier

RaySearch to exhibit the latest news for particle therapy at PTCOG 58

Varian announces acquisitions of Endocare and Alicon

Flash irradiation delivered in a IBA ProteusONE proton therapy treatment room

Herlev University Hospital treats first patient in Denmark on Varian Halcyon system

Varian-equipped New York Proton Therapy Center opens with ribbon cutting event

Varian to host FlashForward Consortium meeting at PTCOG58

AngioDynamics announces first patient enrolled in NanoKnife DIRECT clinical study for stage III pancreatic cancer treatment

Press releases may be edited for formatting or style
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife® Irreversible Electroporation (IRE) “Data IRE Cancer Treatment” clinical study (DIRECT).

The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows the United States Food and Drug Administration’s (FDA) April 1, 2019 approval of AngioDynamics’ investigational device exemption (IDE) application.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.



“The enrollment of our first patient soon after receiving FDA approval is a strong signal that clinicians are eager to evaluate treatment alternatives that improve the dismal prognosis for Stage III pancreatic cancer patients,” said Brent Boucher, AngioDynamics Senior Vice President and General Manager of Oncology. “We look forward to confirming that our proprietary NanoKnife technology offers a compelling alternative to the current standard of care and believe that this study will provide a pivotal dataset for claims and reimbursement purposes.”

AngioDynamics’ DIRECT clinical study features a comprehensive data collection strategy that will provide meaningful clinical information to healthcare professionals, support a regulatory indication for the treatment of Stage III pancreatic cancer, and facilitate reimbursement for hospitals and treating physicians. The next-generation study is classified as a Category B IDE by the FDA, which allows participating sites to obtain coverage for procedures performed in addition to any related routine costs.

“We are pleased to be the first enrolling site. The DIRECT Study represents an important milestone in the standardization of care for patients with Stage III pancreatic cancer. Our goal is to generate important data that should standardize and optimize the use of IRE in the treatment of locally advanced pancreatic cancer, significantly improving outcomes for patients with this late-stage diagnosis,” said Dr. Robert C.G. Martin, Co-Principal Investigator of the DIRECT Study and Surgical Oncologist at the University of Louisville.

The DIRECT Study comprises a Randomized Controlled Trial at up to 15 sites, as well as a Real-World Evidence, next-generation registry at up to 30 sites, each with a NanoKnife System treatment arm and a control arm. AngioDynamics expects each NanoKnife arm to consist of approximately 250 patients with an equal number of control patients. The primary endpoint of the study is overall survival.
  Pages: 1 - 2 >>

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

E-Mail-Werbung
Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Übersicht
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Gesundheitsdienstleister
Alle Gesundheitsdienstleister-Tools anzeigen
Jobs/Training
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich auf DOTmed bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Servicetechniker
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED